The discovery of drugs for Alzheimer’s disease (AD) therapy that can also permeate the blood brain barrier (BBB) is very difficult
owing to its specificity and restrictive nature. The BBB disruption or the administration of the drug directly into the brain is not an
option due to toxic effects and low diffusion of the therapeutic molecule in the brain parenchyma. A promising approach for drug systemic
delivery to the central nervous system is the use of nanosized carriers. The therapeutic potential of certain nanopharmaceuticals for
AD has already been demonstrated in vivo after systemic delivery. They are based on i) conjugates of drug and monoclonal antibodies
against BBB endogenous receptors; ii) cationized or end terminal protected proteins/peptides; iii) liposomes and polymeric nanoparticles
coated with polysorbate 80, cationic macromolecules or antibodies against BBB receptors/amyloid beta-peptides. Optimization and further
validation of these systems are needed.
Keywords: Alzheimer’s disease, Brain drug-targeting, blood brain barrier, parenteral route administration, monoclonal antibodies, liposomes,
polymeric nanoparticles, therapeutic peptides.
Rights & PermissionsPrintExport
Published on: 26 September, 2013
Page: [6635 - 6646]